Based on TCGA data analysis, we found that SNHG7 was upregulated in 17 of the 33 cancer types investigated, including cholangiocarcinoma (CHOL), prostate adenocarcinoma (PRAD), and thyroid carcinoma (THCA) (Figure 1A). Here, SNHG7 is linked to cholangiocarcinoma.